WO2009150470A3 - Suppression of cancers - Google Patents

Suppression of cancers Download PDF

Info

Publication number
WO2009150470A3
WO2009150470A3 PCT/GB2009/050666 GB2009050666W WO2009150470A3 WO 2009150470 A3 WO2009150470 A3 WO 2009150470A3 GB 2009050666 W GB2009050666 W GB 2009050666W WO 2009150470 A3 WO2009150470 A3 WO 2009150470A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
cell
suppressing
treating
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2009/050666
Other languages
French (fr)
Other versions
WO2009150470A2 (en
Inventor
Frederic Madec
Phil Lecane
Philip Marks
Keith Foster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntaxin Ltd
Original Assignee
Syntaxin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0810782.3A external-priority patent/GB0810782D0/en
Priority claimed from GB0820965A external-priority patent/GB0820965D0/en
Priority to CA2726092A priority Critical patent/CA2726092A1/en
Priority to JP2011513057A priority patent/JP5799397B2/en
Priority to KR1020117000258A priority patent/KR101731655B1/en
Priority to US12/996,641 priority patent/US10240138B2/en
Priority to BRPI0915142A priority patent/BRPI0915142A8/en
Priority to ES09762019T priority patent/ES2732205T3/en
Priority to CN2009801220928A priority patent/CN102083451A/en
Priority to EP18199184.5A priority patent/EP3473643A1/en
Application filed by Syntaxin Ltd filed Critical Syntaxin Ltd
Priority to AU2009259034A priority patent/AU2009259034B2/en
Priority to EP09762019.9A priority patent/EP2310029B1/en
Publication of WO2009150470A2 publication Critical patent/WO2009150470A2/en
Publication of WO2009150470A3 publication Critical patent/WO2009150470A3/en
Priority to ZA2010/08425A priority patent/ZA201008425B/en
Priority to IL209854A priority patent/IL209854A/en
Anticipated expiration legal-status Critical
Priority to US12/969,826 priority patent/US20110158973A1/en
Priority to US14/250,954 priority patent/US10550377B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention relates to a method for suppressing or treating cancer, in particular to a method for suppressing or treating one or more of colorectal cancer, breast cancer, prostate cancer and/ or lung cancer. The therapy employs use of anon-cytotoxic protease, which is targeted to a growth hormone-secreting cell such as to a pituitary cell.When so delivered, the protease is internalised and inhibits secretion/ transmission of growth hormonefromsaid cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.
PCT/GB2009/050666 2008-06-12 2009-06-11 Suppression of cancers Ceased WO2009150470A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
AU2009259034A AU2009259034B2 (en) 2008-06-12 2009-06-11 Suppression of cancers
EP09762019.9A EP2310029B1 (en) 2008-06-12 2009-06-11 Fusion proteins for use in the treatment of cancer
JP2011513057A JP5799397B2 (en) 2008-06-12 2009-06-11 Cancer suppression
KR1020117000258A KR101731655B1 (en) 2008-06-12 2009-06-11 Suppression of cancers
US12/996,641 US10240138B2 (en) 2008-06-12 2009-06-11 Polypeptides that bind to and inhibit secretion from growth hormone secreting cells
BRPI0915142A BRPI0915142A8 (en) 2008-06-12 2009-06-11 POLYPEPTIDES, NUCLEIC ACID AND USES THEREOF
ES09762019T ES2732205T3 (en) 2008-06-12 2009-06-11 Fusion proteins for use in cancer treatment
CN2009801220928A CN102083451A (en) 2008-06-12 2009-06-11 cancer suppression
EP18199184.5A EP3473643A1 (en) 2008-06-12 2009-06-11 Fusion proteins for use in the treatemnt of cancer
CA2726092A CA2726092A1 (en) 2008-06-12 2009-06-11 Suppression of cancers
ZA2010/08425A ZA201008425B (en) 2008-06-12 2010-11-24 Suppression of cancers
IL209854A IL209854A (en) 2008-06-12 2010-12-08 Polypeptide, nucleic acid sequence encoding such a polypeptide and the use of such a polypeptide in the preparation of a medicament for suppressing cancer
US12/969,826 US20110158973A1 (en) 2008-06-12 2010-12-16 Suppression of cancers
US14/250,954 US10550377B2 (en) 2008-06-12 2014-04-11 Suppression of prostate cancer using a targeted clostridial neurotoxin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0810782.3 2008-06-12
GBGB0810782.3A GB0810782D0 (en) 2008-06-12 2008-06-12 Suppression of cancers
GB0820965A GB0820965D0 (en) 2008-11-17 2008-11-17 Suppression of cancers
GB0820965.2 2008-11-17

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US12/996,641 A-371-Of-International US10240138B2 (en) 2008-06-12 2009-06-11 Polypeptides that bind to and inhibit secretion from growth hormone secreting cells
US12/969,826 Continuation-In-Part US20110158973A1 (en) 2008-06-12 2010-12-16 Suppression of cancers
US14/250,954 Continuation US10550377B2 (en) 2008-06-12 2014-04-11 Suppression of prostate cancer using a targeted clostridial neurotoxin

Publications (2)

Publication Number Publication Date
WO2009150470A2 WO2009150470A2 (en) 2009-12-17
WO2009150470A3 true WO2009150470A3 (en) 2010-07-15

Family

ID=41417178

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/050666 Ceased WO2009150470A2 (en) 2008-06-12 2009-06-11 Suppression of cancers

Country Status (13)

Country Link
US (2) US10240138B2 (en)
EP (2) EP3473643A1 (en)
JP (1) JP5799397B2 (en)
KR (1) KR101731655B1 (en)
CN (2) CN107446053A (en)
AU (1) AU2009259034B2 (en)
BR (1) BRPI0915142A8 (en)
CA (1) CA2726092A1 (en)
ES (1) ES2732205T3 (en)
HK (1) HK1246809A1 (en)
IL (1) IL209854A (en)
WO (1) WO2009150470A2 (en)
ZA (1) ZA201008425B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
GB0803068D0 (en) 2008-02-20 2008-03-26 Health Prot Agency Cross-linked biological indicator
US10466245B2 (en) 2008-02-20 2019-11-05 The Secretary Of State For Health Covalently linked thermostable kinase for decontamination process validation
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
CA2727082C (en) * 2008-06-12 2019-02-26 Syntaxin Limited Fusion proteins for use in suppression of acromegaly
GB0820970D0 (en) * 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
AU2015268754B2 (en) * 2008-11-17 2018-01-18 Ipsen Bioinnovation Limited Suppression of cancer
GB0903006D0 (en) * 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
KR20170058446A (en) 2010-08-13 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 Peptidomimetic macrocycles
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
AR088392A1 (en) 2011-10-18 2014-05-28 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCICLES
CA2862038C (en) 2012-02-15 2021-05-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
BR112015009470A2 (en) 2012-11-01 2019-12-17 Aileron Therapeutics Inc disubstituted amino acids and their methods of preparation and use
WO2014139468A1 (en) * 2013-03-15 2014-09-18 Admark Healthcare, Llc Fusion protein molecules and method of use
US9216210B2 (en) * 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN109153712B (en) 2016-04-19 2022-09-16 格里芬制药国际公司 PEG biological active peptide and its use
TW201814045A (en) 2016-09-16 2018-04-16 英商艾普森生物製藥有限公司 Method for producing di-chain clostridial neurotoxins
WO2018060351A1 (en) 2016-09-29 2018-04-05 Ipsen Biopharm Limited Hybrid neurotoxins
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
UA128185C2 (en) 2018-01-29 2024-05-01 Іпсен Біофарм Лімітед A NON-NEURONAL SNARE-CLEAVING BOTULINE NEUROTOXIN
GB201815817D0 (en) * 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
CN114933657B (en) * 2021-08-25 2024-02-02 上海交通大学医学院 Nerve growth factor mutant recombinant protein and its application

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042223A1 (en) * 1996-05-03 1997-11-13 The Administrators Of The Tulane Educational Fund hGH-RH(1-29)NH2 ANALOGUES HAVING ANTAGONISTIC ACTIVITY
WO2004076634A2 (en) * 2003-02-24 2004-09-10 Ira Sanders Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease
US20050031648A1 (en) * 1999-12-07 2005-02-10 Allergan, Inc. Methods for treating diverse cancers
WO2005016953A2 (en) * 2003-08-05 2005-02-24 The Administrators Of The Tulane Educational Fund (A Not For Profit Corporation) Antagonistic analogs of gh-rh (2003)
WO2006026780A1 (en) * 2004-09-01 2006-03-09 Allergan, Inc. Degradable clostridial toxins
WO2006099590A2 (en) * 2005-03-15 2006-09-21 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US100571A (en) 1870-03-08 Improved stove-shelf and drier
US248771A (en) 1881-10-25 Lap-ring
US394727A (en) 1888-12-18 scully
US422A (en) 1837-10-06 Galley ob cooking-stove for ships of wab
US282328A (en) 1883-07-31 eager
US397169A (en) 1889-02-05 campbell
US317941A (en) 1885-05-12 Half to theodoee f
US173311A (en) 1876-02-08 Improvement in stone-gleaners
US502438A (en) 1893-08-01 Apparatus for producing cold and ice
US440039A (en) 1890-11-04 Cough remedy
US257998A (en) 1882-05-16 Harrow
US376555A (en) 1888-01-17 Banana-carrier
US207759A (en) 1878-09-03 Improvement in accordions
US520225A (en) 1894-05-22 Skirt-protecting garment
US8057A (en) 1851-04-22 Cofkee-roasteb
US204171A (en) 1878-05-28 Improvement in rings for preventing hogs from rooting
US261885A (en) 1882-08-01 Ornamental glass and process of etching the same
US4291022A (en) 1975-03-11 1981-09-22 Sandoz Ltd. Organic compounds
US4133782A (en) 1976-06-07 1979-01-09 The Salk Institute For Biological Studies Somatostatin analogs with dissociated biological activities
US4190575A (en) 1977-12-27 1980-02-26 American Home Products Corporation Polypeptides related to somatostatin
IT1105131B (en) 1977-06-08 1985-10-28 Merck & Co Inc ANALOGS OF SOMATOSTATINA EQUIPPED WITH MORE LONG AND GREATER BIOLOGICAL ACTIVITY AND RELATIVE PROTECTION PROCEDURE
US4211693A (en) 1977-09-20 1980-07-08 The Salk Institute For Biological Studies Peptides with para-substituted phenylalanine
LU78191A1 (en) 1977-09-28 1979-05-25 Ciba Geigy Ag METHOD FOR PRODUCING NEW CYCLOPEPTIDES
US4190648A (en) 1979-03-13 1980-02-26 Merck & Co., Inc. Peptides having somatostatin activity
US4316890A (en) 1979-03-16 1982-02-23 Ciba-Geigy Corporation Peptides and processes for the manufacture thereof
US4328214A (en) 1979-07-04 1982-05-04 Ciba-Geigy Corporation Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture
US4235886A (en) 1979-10-31 1980-11-25 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4310518A (en) 1979-10-31 1982-01-12 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4369179A (en) 1979-12-14 1983-01-18 Ciba-Geigy Corporation Acylpeptides
US4282143A (en) 1980-06-13 1981-08-04 American Home Products Corporation Octapeptides lowering growth hormone
US4360516A (en) 1981-04-13 1982-11-23 Merck & Co., Inc. Modified D-retro cyclic hexapeptide somatostatin analogs
ATE14226T1 (en) 1981-12-24 1985-07-15 Ciba Geigy Ag CYCLIC OCTAPEPTIDES AND PHARMACEUTICAL PREPARATIONS THEREOF, AND PROCESSES FOR THE MANUFACTURE THE SAME AND THEIR USE.
FR2522655B1 (en) 1982-03-05 1987-03-06 Sanofi Sa SOMATOSTATIN ANALOGS HAVING HYDRAZIDE-LIKE BINDING AND DRUGS CONTAINING SAME
US4522813A (en) 1983-10-27 1985-06-11 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4659693A (en) 1984-04-30 1987-04-21 Syntex (U.S.A.) Inc. N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
US4650787A (en) 1985-04-25 1987-03-17 Schally Andrew Victor Biologically active octapeptides
US4725577A (en) 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
US4585755A (en) 1985-04-29 1986-04-29 Merck & Co., Inc. Cyclic and bridged cyclic somatostatin analogs useful as local anti-inflammatory agents
US4904642A (en) 1985-09-12 1990-02-27 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4853371A (en) 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4803261A (en) 1986-06-27 1989-02-07 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide
NL194729C (en) 1986-10-13 2003-01-07 Novartis Ag Process for the preparation of peptide alcohols via solid phase.
US4871717A (en) 1987-01-07 1989-10-03 Administrators Of The Tulane Educational Fund Peptides
JP2795449B2 (en) 1987-09-24 1998-09-10 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド Therapeutic peptides
US5084555A (en) 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
JPH03502328A (en) 1988-02-01 1991-05-30 ジ・アップジョン・カンパニー Renin-inhibitory peptides with polar terminal groups
ZA895838B (en) 1988-08-18 1991-03-27 Syntex Inc Pharmaceutical compounds
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68928667T2 (en) 1988-10-14 1998-10-01 Univ Tulane PEPTIDE AS A MEDICINAL PRODUCT
CA2012115C (en) 1989-03-15 2001-07-03 Biomeasure, Inc. Iodinated somatostatins
JP2882679B2 (en) 1989-04-26 1999-04-12 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド Linear somatostatin analog
ES2091907T3 (en) 1989-12-08 1996-11-16 Univ Tulane SOMATOSTINA OCTAPEPTIDE ANALOGS WITH A THREONIN IN THE SIXTH POSITION.
EP0527914A4 (en) 1990-05-04 1993-08-11 The Administrators Of The Tulane University Educational Fund Novel synthetic grf analogs
EP0531342A1 (en) 1990-05-09 1993-03-17 The Administrators Of The Tulane Educational Fund Cyclized and linear therapeutic peptides
IT1240643B (en) 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa BIOLOGICALLY ACTIVE PEPTIDES CONTAINING IN 2-ALCHYL TRIPTOFANE CHAIN
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
HU207104B (en) 1991-01-25 1993-03-01 Biosignal Kutato Fejlesztoe Kf Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds
AU662731B2 (en) 1991-04-09 1995-09-14 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
US6083915A (en) 1991-05-10 2000-07-04 Biomeasure, Inc. Method for treating liver cancer
AU3658093A (en) 1992-02-10 1993-09-03 Seragen, Inc. Desensitization to specific allergens
US5240561A (en) 1992-02-10 1993-08-31 Industrial Progress, Inc. Acid-to-alkaline papermaking process
AU5668894A (en) 1992-11-13 1994-06-08 The Administrators Of The Tulane Eductional Fund Ghrh agonists
WO1994011397A1 (en) 1992-11-13 1994-05-26 The Administrators Of The Tulane Educational Fund Ghrh agonists
EP0788509B1 (en) 1993-08-09 2003-05-28 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Therapeutic peptide derivatives
US5550212A (en) 1993-12-17 1996-08-27 The Administrators Of The Tulane Educational Fund Analogues of hGH-RH(1-29)NH2 having antagonistic activity
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
ATE170873T1 (en) 1995-03-13 1998-09-15 Biomeasure Inc BOMBESIN ANALOGUE
CA2218173A1 (en) 1995-04-14 1996-10-17 The Administrators Of The Tulane Educational Fund Analogs of growth hormone-releasing factor
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
AU3215597A (en) 1996-08-30 1998-03-19 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
SE507528C2 (en) 1996-10-16 1998-06-15 Teknoskand Invent Ab Locking
US5968903A (en) 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
DK1084146T3 (en) 1998-05-13 2003-02-03 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Hybrid protein for inhibiting the degranulation of mastocytes and their use
US6380265B1 (en) 1998-07-09 2002-04-30 W. R. Grace & Co.-Conn. Dispersion of fine porous inorganic oxide particles and processes for preparing same
ES2205849T3 (en) 1998-07-22 2004-05-01 Osprey Pharmaceuticals Limited CONJUGATED TO TREAT INFLAMMATORY ALTERATIONS AND ASSOCIATED WITH TISSULAR DAMAGES.
JP2002521456A (en) 1998-07-30 2002-07-16 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス How to use somatostatin analogs
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US8790897B2 (en) * 1998-08-25 2014-07-29 Syntaxin Ltd. Treatment of mucus hypersecretion
US6057422A (en) 1998-11-25 2000-05-02 The Administrators Of The Tulane Educational Fund Antagonistic analogs of GH-RH inhibiting IGF-I and -II
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
CZ20014297A3 (en) 1999-06-04 2002-06-12 Societe De Conseils De Recherches Et D´Application Compound, method for inducing effect of neuromedin B receptor agonist and somatostatin receptor, pharmaceutical preparation and treatment method
US20080032931A1 (en) * 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US20030180289A1 (en) 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7369973B2 (en) * 2000-06-29 2008-05-06 Object Reservoir, Inc. Method and system for representing reservoir systems
US6827931B1 (en) * 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
IL156828A0 (en) 2001-01-12 2004-02-08 Waratah Pharmaceuticals Inc Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes
GB0321344D0 (en) 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
GB0426397D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
PL1830872T3 (en) * 2004-12-01 2011-09-30 Sec Dep For Health Fusion proteins
ES2369558T3 (en) 2005-09-19 2011-12-01 Allergan, Inc. CLOSTRIDIAL TOXINS AND ACTIVABLE CLOSTRIDIAL TOXINS.
WO2007106115A1 (en) 2006-03-14 2007-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
EP1834962A1 (en) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGylated mtutated Clostridium botulinum toxin
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
AU2007272515B2 (en) * 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
JP2009543558A (en) 2006-07-11 2009-12-10 アラーガン、インコーポレイテッド Modified clostridial toxin with enhanced translocation ability and enhanced targeting activity
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
GB0815264D0 (en) 2008-08-21 2008-09-24 Syntaxin Ltd Non-cytotoxic proteins
AU2010282278A1 (en) * 2009-08-14 2012-03-15 Allergan, Inc. Methods of treating cancer using glucagon-like hormone retargeted endopeptidases
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042223A1 (en) * 1996-05-03 1997-11-13 The Administrators Of The Tulane Educational Fund hGH-RH(1-29)NH2 ANALOGUES HAVING ANTAGONISTIC ACTIVITY
US20050031648A1 (en) * 1999-12-07 2005-02-10 Allergan, Inc. Methods for treating diverse cancers
WO2004076634A2 (en) * 2003-02-24 2004-09-10 Ira Sanders Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease
WO2005016953A2 (en) * 2003-08-05 2005-02-24 The Administrators Of The Tulane Educational Fund (A Not For Profit Corporation) Antagonistic analogs of gh-rh (2003)
WO2006025976A1 (en) * 2004-08-27 2006-03-09 Allergan, Inc. Methods for treating cancer
WO2006026780A1 (en) * 2004-09-01 2006-03-09 Allergan, Inc. Degradable clostridial toxins
WO2006099590A2 (en) * 2005-03-15 2006-09-21 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JACOBSSON G, HÅKANSSON ML, HULTING AL, MEISTER B.: "Botulinum neurotoxin F, a VAMP-specific endopeptidase, inhibits Ca(2+)-stimulated GH secretion from rat pituitary cells", REGUL PEPT, vol. 71, no. 1, 23 July 1997 (1997-07-23), XP002581489 *
SCHALLY ANDREW V ET AL: "Antagonists of growth hormone-releasing hormone in oncology", CURRENT TOPICS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS LTD, NETHERLANDS, vol. 9, no. 3, 1 March 2006 (2006-03-01), pages 163 - 170, XP009120779, ISSN: 1568-0266 *

Also Published As

Publication number Publication date
AU2009259034B2 (en) 2013-10-31
EP2310029A2 (en) 2011-04-20
BRPI0915142A2 (en) 2016-02-16
KR20110028492A (en) 2011-03-18
JP2011523859A (en) 2011-08-25
ES2732205T3 (en) 2019-11-21
IL209854A (en) 2013-09-30
CN102083451A (en) 2011-06-01
KR101731655B1 (en) 2017-05-11
EP3473643A1 (en) 2019-04-24
IL209854A0 (en) 2011-02-28
ZA201008425B (en) 2012-04-25
CA2726092A1 (en) 2009-12-17
JP5799397B2 (en) 2015-10-28
US10240138B2 (en) 2019-03-26
CN107446053A (en) 2017-12-08
US20140219983A1 (en) 2014-08-07
WO2009150470A2 (en) 2009-12-17
US10550377B2 (en) 2020-02-04
HK1246809A1 (en) 2018-09-14
EP2310029B1 (en) 2019-04-03
US20110165137A1 (en) 2011-07-07
AU2009259034A1 (en) 2009-12-17
BRPI0915142A8 (en) 2018-01-02

Similar Documents

Publication Publication Date Title
WO2009150470A3 (en) Suppression of cancers
WO2011037643A3 (en) Compositions and methods for detecting and treating prostate carcinoma
WO2007127010A3 (en) Diarylthiohydantoin compounds
MX2022009759A (en) Diarylhydantoin compounds.
WO2008094708A3 (en) Activin-actriia antagonists and uses for treating or preventing breast cancer
WO2010099161A8 (en) Micrornas in never-smokers and related materials and methods
WO2008060645A3 (en) Combinatorial therapy involving alpha5beta1 antagonists
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
WO2009108860A8 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2011041336A3 (en) Treating notch1-antagonist-resistant cancer (s) using notch3 antagonists
IN2012DN02046A (en)
WO2011130164A3 (en) Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
WO2008061020A3 (en) Methods of treating, diagnosing or detecting cancer
WO2009150547A3 (en) 2-pyridyl substituted imidazoles as alk4 and/or alk4 inhibitors
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
WO2007100920A3 (en) Diagnosis and treatment of prostate cancer
WO2008134752A3 (en) Methods and compositions for the treatment of cancer
WO2008092099A3 (en) Compositions and methods for treating hematopoietic malignancies
WO2010127197A3 (en) Method and composition for treating diabetic ketoacidosis
WO2007056049A3 (en) Molecular profiling of cancer
WO2012170742A3 (en) Treatment and prevention of cancer with hmgb1 antagonists
WO2011100642A3 (en) Method for treating hematological cancers
WO2011085134A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
WO2012061086A3 (en) Method of treating neuroendocrine tumors
WO2011128701A3 (en) Cancer methods

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980122092.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09762019

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2726092

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 209854

Country of ref document: IL

Ref document number: 2009259034

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2011513057

Country of ref document: JP

Ref document number: 8853/DELNP/2010

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20117000258

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009762019

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009259034

Country of ref document: AU

Date of ref document: 20090611

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0915142

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101213